Disclosed are multifunctional compounds represented by structural formula (I): ##STR00001##
methods of producing compounds represented by structural formula (I) and their use in inhibiting corrosion in corrodible material.

The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. This compound provides a prophylactic or therapeutic agent effective for bacterial infections when used in combination with β-lactam-based drugs or used as a single agent. The present invention also provides a prophylactic or therapeutic agent effective for treating various diseases, by being used in combination with β-lactam-based drugs.

A process for detecting oil or lubricant contamination in the production of an article by adding a Stokes-shifting taggant to an oil or lubricant of a machine utilized to produce the article or a component thereof, irradiating the articles produced with a first wavelength of radiation, and monitoring the articles for emission of radiation at a second wavelength. The taggant can be in the form of a composition containing a Stokes-shifting taggant, which absorbs radiation at a first wavelength and emits radiation at a second wavelength, different from said first wavelength, dissolved or dispersed in an oil or lubricant.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

This disclosure relates to an SO.sub.2-based electrolyte for a rechargeable battery cell containing at least one conducting salt of the Formula (I) ##STR00001##
wherein M is a metal selected from the group consisting of alkali metals, alkaline earth metals, metals of group 12 of the periodic table of the elements and aluminum; x is an integer from 1 to 3; the substituents R, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from the group consisting of C.sub.1-C.sub.10 alkyl, C.sub.2-C.sub.1 alkenyl, C.sub.2-C.sub.1 alkynyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.6-C.sub.14 aryl, and C.sub.5-C.sub.14 heteroaryl; and Z is aluminum or boron.

This disclosure relates to an SO.sub.2-based electrolyte for a rechargeable battery cell containing at least one conducting salt of the Formula (I) ##STR00001##
wherein M is a metal selected from the group consisting of alkali metals, alkaline earth metals, metals of group 12 of the periodic table of the elements and aluminum; x is an integer from 1 to 3; the substituents R, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from the group consisting of C.sub.1-C.sub.10 alkyl, C.sub.2-C.sub.1 alkenyl, C.sub.2-C.sub.1 alkynyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.6-C.sub.14 aryl, and C.sub.5-C.sub.14 heteroaryl; and Z is aluminum or boron.

Novel polymorphic forms of tavaborole, Form A and Form B, and methods of making same are disclosed. Methods are disclosed for the manufacture of the novel polymorphic Forms A and B. Methods include dissolving tavaborole in a pharmaceutically acceptable solvent to obtain a mixture, heating the mixture until a clear solution is obtained, cooling the clear solution, stirring the clear solution to obtain a crystalline product, filtering the crystalline product, and drying the crystalline product to obtain the pharmaceutically acceptable crystalline form of tavaborole. Pharmaceutical composition are disclosed including a pharmaceutically acceptable crystalline form of tavaborole Form A and/or Form B.

Novel polymorphic forms of tavaborole, Form A and Form B, and methods of making same are disclosed. Methods are disclosed for the manufacture of the novel polymorphic Forms A and B. Methods include dissolving tavaborole in a pharmaceutically acceptable solvent to obtain a mixture, heating the mixture until a clear solution is obtained, cooling the clear solution, stirring the clear solution to obtain a crystalline product, filtering the crystalline product, and drying the crystalline product to obtain the pharmaceutically acceptable crystalline form of tavaborole. Pharmaceutical composition are disclosed including a pharmaceutically acceptable crystalline form of tavaborole Form A and/or Form B.

A process for preparing oligo ethylene glycol methyl ether borate involves feeding boric acid and oligo ethylene glycol monomethyl ether into a reactor, and reacting to obtain a raw product containing oligo ethylene glycol methyl ether borate, water, and unreacted boric acid and oligo ethylene glycol monomethyl ether. The raw product is fed to a reactive distillation device and boric acid is reacted with oligo ethylene glycmonomethyl ether for full conversion of boric acid. A distillate stream containing water is transferred from the top of the reactive distillation device to a condenser, and a condensed liquid stream is recycled to the top of the reactive distillation device. A bottom product stream containing oligo ethylene glycol methyl ether borate is withdrawn from the reactive distillation device. The bottom product stream is partially recycled to a reboiler. The resulting vapor stream is recycled to the bottom of the reactive distillation device.